Coherus Oncology Inc (CHRS)

05:13 AM

Coherus Biosciences (CHRS) is one of the best penny stocks, here is why - MSN

05:13 AM

Apr 02, 2026

Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - marketbeat.com

Apr 02, 2026

Apr 01, 2026

Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk - Yahoo Finance

Apr 01, 2026

Mar 31, 2026

Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why - Yahoo Finance

Mar 31, 2026

Mar 27, 2026

Coherus Oncology (CHRS) upgraded to buy: Here's what you should know - msn.com

Mar 27, 2026

Mar 26, 2026

Vanguard disaggregates holdings; 0% stake in Coherus (NASDAQ: CHRS) - Stock Titan

Mar 26, 2026

Mar 26, 2026

If You Invested $1,000 in Coherus (CHRS) - stocktitan.net

Mar 26, 2026

Mar 25, 2026

Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline - openpr.com

Mar 25, 2026

Mar 25, 2026

Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Mar 25, 2026

Mar 24, 2026

Coherus Oncology (NASDAQ:CHRS) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat

Mar 24, 2026

Mar 19, 2026

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Mar 19, 2026

Mar 18, 2026

Coherus Oncology announces proposed public offering of common stock - MSN

Mar 18, 2026

Mar 17, 2026

CHRS Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 17, 2026

Mar 16, 2026

Coherus BioSciences Q4 2025 earnings preview - MSN

Mar 16, 2026

Mar 16, 2026

Coherus Oncology (CHRS) Short Interest & Short Float | Updated Mar 2026 - MarketBeat

Mar 16, 2026

Mar 14, 2026

Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf. - MarketBeat

Mar 14, 2026

Mar 14, 2026

Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen - MarketBeat

Mar 14, 2026

Mar 13, 2026

Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Mar 13, 2026

Mar 11, 2026

Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN

Mar 11, 2026

Mar 11, 2026

Coherus Oncology (CHRS) Revenue Gains Contrast With Persistent US$46 Million Quarterly Losses - simplywall.st

Mar 11, 2026

Mar 11, 2026

Coherus outlines $175M annualized LOQTORZI target by 2028 as commercial expansion accelerates - MSN

Mar 11, 2026

Mar 10, 2026

Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift By Investing.com - Investing.com Canada

Mar 10, 2026

Mar 10, 2026

CHRS: Rapid oncology pipeline progress and strong LOQTORZI sales drive growth and pivotal trial plans - TradingView

Mar 10, 2026

Mar 10, 2026

Coherus Oncology Doubles LOQTORZI Revenue in 2025, Advances Oncology Pipeline and Significantly Reduces Debt 1 - Minichart

Mar 10, 2026

Mar 10, 2026

Oppenheimer reiterates Coherus Biosciences stock rating at Outperform By Investing.com - Investing.com India

Mar 10, 2026

Mar 10, 2026

Oppenheimer reiterates Coherus Biosciences stock rating at Outperform - Investing.com

Mar 10, 2026

Mar 10, 2026

Coherus Oncology, Inc. 2025 Annual Report – LOQTORZI Sales Growth, Pipeline Advances, and Strategic Shift to Immuno-Oncology - Minichart

Mar 10, 2026

Mar 10, 2026

Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

Mar 10, 2026

Mar 09, 2026

Coherus Oncology Q4 2025 Earnings Call Transcript - MarketBeat

Mar 09, 2026

Mar 09, 2026

Coherus Oncology Inc (CHRS) Q4 2025 Earnings Call Highlights: St - GuruFocus

Mar 09, 2026

Mar 09, 2026

Coherus Oncology (CHRS) Sees Strong Growth with LOQTORZI - gurufocus.com

Mar 09, 2026

Mar 09, 2026

Coherus Oncology Reports Q4 Earnings Loss - National Today

Mar 09, 2026

Mar 09, 2026

Coherus Oncology Q4 Earnings Call Highlights - MarketBeat

Mar 09, 2026

Mar 09, 2026

CHRS: LOQTORZI sales doubled, debt slashed, and key oncology trials advance toward 2026 data - TradingView

Mar 09, 2026

Mar 09, 2026

CHRS: LOQTORZI revenue doubled, debt slashed, and pipeline advances set up major 2026 milestones - TradingView

Mar 09, 2026

Mar 09, 2026

CHRS Q4 Revenue Falls Short but Strategic Shift Shows Promise - GuruFocus

Mar 09, 2026

Mar 09, 2026

Coherus Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 09, 2026

Mar 09, 2026

Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 09, 2026

Mar 09, 2026

Coherus Oncology Q4 2025 Results: Quarterly Loss, Annual ProfitNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform

Mar 09, 2026

Mar 09, 2026

Coherus Oncology: Fourth Quarter Financial Results Overview - Bitget

Mar 09, 2026

Mar 09, 2026

Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat

Mar 09, 2026

Mar 09, 2026

Coherus Oncology (NASDAQ: CHRS) reports 2025 results and sharp debt cut - Stock Titan

Mar 09, 2026

Mar 09, 2026

Coherus Oncology: Q4 Earnings Snapshot - Barchart.com

Mar 09, 2026

Mar 09, 2026

Coherus Oncology Q4 revenue misses estimates - TradingView

Mar 09, 2026

Mar 09, 2026

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - The Manila Times

Mar 09, 2026

Mar 09, 2026

BRIEF-Coherus Oncology Q4 Sales USD 12.748 Million Vs. IBES Estimate USD 13.9 Million - TradingView

Mar 09, 2026

Mar 09, 2026

Cancer drug LOQTORZI sales double to $40.8M as trials near - Stock Titan

Mar 09, 2026